Small molecules vs biologics

Welcome to this lecture on small molecules versus biologics, providing an overview of the essential differences between small molecule drugs and biologics, including their molecular structure, mechanisms of action, and pharmacokinetic properties. We will explore how these differences impact manufacturing, clinical application, and patient outcomes. Finally, we will discuss how therapeutic strategies increasingly leverage both classes, ensuring treatments are tailored to diverse patient needs. Today's therapeutic landscape features two major drug classes, small molecules and biologics. Small molecules are low molecular weight compounds, often made by chemical synthesis. Biologics are typically large complex molecules like proteins, monoclonal antibodies or peptides produced using living systems. While biologics have gained prominence and redefined treatments, small molecules still remain essential in many therapies. Recognizing the differences between these drug classes is important for both clinicians and patients. At the molecular level, differences are striking. Small molecules typically weigh under 500 Daltons and have simple, well defined structures like aspirin and many oral drugs. By contrast, biologics range from a few thousand to over 150,000 Daltons, such as monoclonal antibodies with highly complex three dimensional structures and modifications. This complexity makes biologics functionally powerful,